News
BRTX
1.370
-4.86%
-0.070
Optimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic Advances
TipRanks · 2d ago
BIORESTORATIVE THERAPIES INC <BRTX.O>: MAXIM GROUP CUTS TARGET PRICE TO $6 FROM $10
Reuters · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals
Dow Jones Industrial Average up 0.13% after upbeat results from health insurer UnitedHealth. Morgan Stanley, Intra-Cellular Therapies, China SXT Pharmaceuticals among top stocks on the move. Higher Treasury yields and conflict in the Middle East keep investors on edge.
Reuters · 3d ago
BioRestorative Therapies Shares Rise 17% After FDA Clears Phase 2 Study Protocol Amendment
BioRestorative Therapies shares were up 17% to $1.55. The company says FDA has cleared an amendment to the protocol of a Phase 2 study of BRTX-100 for treating chronic lumbar disc disease. The protocol amendment removes saline injection in the study and replaces it with a sham injection.
Dow Jones · 3d ago
BioRestorative gains as FDA clears amendment to study on cell therapy candidate
BioRestorative Therapies shares rose +15.91% to $1.53. FDA clears amendment to study on cell therapy candidate for chronic lumbar disc disease. The company's shares rose as much as 15.9%. The company says the study will now use a sham injection to treat the disease.
Seeking Alpha · 3d ago
BIORESTORATIVE THERAPIES SHARES UP 9.5% AFTER U.S. FDA CLEARS CHANGE TO CELL THERAPY'S MID-STAGE STUDY
Reuters · 3d ago
BUZZ-BioRestorative Therapies up as FDA clears change to study on cell therapy
BioRestorative Therapies shares rise 15.2% to $1.52 premarket. FDA clears change to study on cell therapy for chronic lumbar disc disease. Company says amendment replaces saline injection in the placebo group with a sham injection. Stock down 24% YTD.
Reuters · 3d ago
Market-Moving news for April 16th
BioRestorative Therapies shares are trading higher after the company announced FDA clearance of its BRTX-100 clinical study protocol amendment. Cullinan Therapeutics to pursue development of CLN-978 in autoimmune diseases. Intra-Cellular reports Phase 3 topline results from major depressive disorder study.
Benzinga · 3d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Dynatronics (NASDAQ:DYNT) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap rose to $3.3 million. Inovio Pharmaceuticals shares fell 24.3% during the session. Akanda shares increased by 23.0% and BioRestorative Therapies shares moved upwards.
Benzinga · 3d ago
BIORESTORATIVE THERAPIES INC - PROTOCOL AMENDMENT REMOVES SALINE INJECTION IN CONTROL ARM OF STUDY AND REPLACES IT WITH A SHAM INJECTION
Reuters · 3d ago
Weekly Report: what happened at BRTX last week (0408-0412)?
Weekly Report · 4d ago
Dominari Holdings And 2 Other Stocks Under $3 Insiders Are Buying
When insiders purchase or sell shares, it indicates confidence or concern around the company's prospects. Insider transactions for penny stocks include Dominari Holdings Inc, Lion Copper and Gold Corp and BioRestorative Therapies Inc. The Dow Jones index closed lower by over 400 points on Wednesday.
Benzinga · 04/11 12:41
BioRestorative Therapies stock up on partnership with Galen Patient Recruitment
BioRestorative Therapies shares rise about 12% premarket after partnership with Galen Patient Recruitment. The collaboration is expected to help accelerate the completion of patient enrollment in the ongoing Phase 2 study of BRTX-100 in chronic lumbar disc disease.
Seeking Alpha · 04/08 13:19
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack
Microstrategy, Apartment Income REIT, Marathon Digital among premarket gainers' pack. Auddia AUUD +123% on bagging a U.S. Patent for the core AI technology it uses in its radio app. Bitcoin again surpassed the $72,000 level.
Seeking Alpha · 04/08 13:10
Weekly Report: what happened at BRTX last week (0401-0405)?
Weekly Report · 04/08 12:26
PERI, ITRM and CADL among pre-market losers
On the Move PERI, ITRM and CADL among pre-market losers. Perion Network Ltd. (PERI) announces preliminary Q1 2024 financial results. ZOOZ Power Ltd. Is one of the companies to report positive results for first quarter of 2024.
Seeking Alpha · 04/08 12:23
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Longeveron (NASDAQ:LGVN) shares moved upwards by 75.0% to $3.85 during Monday's pre-market session. PetVivo Hldgs stock increased by 17.09% and SHL Telemedicine stock moved up by 13.26%. Losers include Supernus Pharmaceuticals and G1 Therapeutics.
Benzinga · 04/08 12:09
BIORESTORATIVE THERAPIES INC - PATIENT ENROLLMENT EXPECTED TO BE COMPLETED IN 2024
Reuters · 04/08 11:45
BIORESTORATIVE THERAPIES PARTNERS WITH GALEN PATIENT RECRUITMENT TO ACCELERATE COMPLETION OF ENROLLMENT IN PHASE 2 TRIAL OF BRTX-100 IN CHRONIC LUMBAR DISC DISEASE
Reuters · 04/08 11:45
More
Webull provides a variety of real-time BRTX stock news. You can receive the latest news about Biorestorative Therapies Inc through multiple platforms. This information may help you make smarter investment decisions.
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). The Company has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs.